7-oh repression of the FDA sons on Kratom

The Trump administration moved Tuesday to add 7-oh, a psychoactive compound derived from the Kratom factory, on the calendar of controlled substances.

The movement specifically targets products with high levels of 7-OH, which occurs naturally in the Kratom in quantities of trace. But the Food and Drug Administration stressed in an advertisement that the application measures are not focused on “Natural Kratom Leaf products”.

“We are not targeting the Kratom leaf or the scrambled Kratom,” said FDA commissioner Marty Makary. “We target a concentrated synthetic by-product which is an opioid.”

Kratom is a natural factory in Southeast Asia that has been used in plant -based medicine for centuries and has become more recently popular – and largely unregulated – in the United States for recreational use or as a pain treatment. But the federal government has long maintained that it has no legitimate use, and states have struggled to regulate it: seven have banished it, while Rhode Island recently became the first state to prohibit Kratom, then to reverse the course.

The planning of 7-OH, or 7-hydroxymitragynin, could bring clarity to the position of the federal government on products related to Kratom: indeed, Kratom itself will remain largely unregulated. However, supplements containing high levels of 7-OH would probably be prohibited.

It is not clear, however, what impact could have the impact on public health. During a press conference, the administration put the movement as preventive, recalling the inability of the FDA and the police to prevent the spread of addictive pain relievers such as oxycontin.

“Public health is supposed to prevent disasters, not just cleaning them after killing thousands and thousands of people,” said Makary.

But Kratom is not a significant source of death by overdose, and there is no registered body of a deadly overdose involving 7-OH but no other substance. When asked if the 7-OH is known to have caused overdoses, Makary has deflected, arguing that there is little data available, and that even doctors dealing with potential overdoses of 7-OH could ignore the compound. However, he described 7-oh “killer”, especially in relation to Kratom himself.

“We think it’s night and day in terms of public health risk,” he said.

Tuesday’s announcement comes only a few weeks after the FDA sent a series of letters warning seven companies against the illegal marketing of 7-OH tablets, gummies and mixtures of drinks, among other articles, but said that only products “can be dangerous” without preventing the potential risk of overdose or death.

Makary said that the FDA recommended that the Drug Enforcement Administration adds 7-OH to Annex I by virtue of the Controlled Substances Act, the highest planning category for products with a high abusive and without medical objective.

The DEA process would first imply publishing a 7-OH planning proposal, then allowing a period of comments from the public before the finalization of the move.

The Kratom industry itself seems to support the repression of the Trump administration against 7-OH products. In an article on social networks, Mac Haddow, a senior official of the American Kratom Association, applauded this decision, calling it a “daring and necessary step”.